Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes
Neutrophil Elastase Inhibition as Adjunctive Therapy to Improve Glucometabolic Variables in Overweight and Obese, Insulin-Resistant Type 2 Diabetic Patients
Sponsor: AstraZeneca
A PHASE2 clinical study on Insulin Resistance and Type 2 Diabetes Mellitus, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 12 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Jun 2021 — Dec 2021 [monthly]
Completed PHASE2
-
Jan 2021 — Jun 2021 [monthly]
Completed PHASE2
-
Sep 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Jul 2019 — Sep 2019 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2018 — Jul 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- National Institutes of Health (NIH)
- Nick Giannoukakis, PhD
- University of Pittsburgh
- University of South Florida
For direct contact, visit the study record on ClinicalTrials.gov .